

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Venetoclax with obinutuzumab for untreated chronic  
lymphocytic leukaemia [ID1402]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final appraisal determination**

(when no ACD was issued)

- |                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|-------------------------------------------------------------------------------------------------------------------------------|

No potential equality issues were identified during the scoping process.
--------------------------------------------------------------------------

- |                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

No equality issues were identified in the company submission, or by the ERG in its report. However, the company's original submission did not include people without a 17p deletion or TP53 mutation for whom FCR or BR is suitable, although this population was in the NICE scope and is included in the <a href="#">marketing authorisation for venetoclax</a> . Patient and professional submissions highlighted that the omission of this population would potentially deny them access to a new treatment option that is well tolerated. The committee addressed this by requesting that the company provide cost-effectiveness analyses comparing venetoclax plus obinutuzumab with FCR and BR in this population, and considered this during the appraisal.
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other potential equality issues have been identified by the committee.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes – in section 3.17 of the FAD.

**Approved by Associate Director (name):** .....Ross Dent.....

**Date:** 18 August 2020

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [ID1402]

Issue date: December 2020